Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus OZURDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus OZURDEX.
INFLAMASE FORTE vs OZURDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Dexamethasone, a potent corticosteroid, reduces inflammation by inhibiting multiple inflammatory cytokines including prostaglandins, leukotrienes, and interleukins. It suppresses the migration of polymorphonuclear leukocytes and reverses increased capillary permeability. The mechanism involves binding to the glucocorticoid receptor, leading to regulation of gene expression that reduces production of inflammatory mediators.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
Single intravitreal implant of 0.7 mg (dexamethasone 700 mcg) in the affected eye; repeat dosing no sooner than 3 months after the prior implant.
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
In the vitreous humor, the half-life is approximately 5-7 months following intravitreal implant administration. Systemic half-life is negligible due to low systemic exposure.
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (≈70%) and urine (≈30%). Less than 1% excreted as unchanged drug.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid